The LANCET: Published on
December, 2022Oral
antivirals have been an important addition to efforts to minimise adverse
COVID-19 outcomes in individuals at high risk.The earlier first
trial of molnupiravir showed only a 30% reduction of hospitalisations and
deaths with molnupiravir compared with placebo. Subsequent observational
studies in...